WO2008014510A2 - Crystalline form a of ibandronic acid and process for the preparation - Google Patents
Crystalline form a of ibandronic acid and process for the preparation Download PDFInfo
- Publication number
- WO2008014510A2 WO2008014510A2 PCT/US2007/074738 US2007074738W WO2008014510A2 WO 2008014510 A2 WO2008014510 A2 WO 2008014510A2 US 2007074738 W US2007074738 W US 2007074738W WO 2008014510 A2 WO2008014510 A2 WO 2008014510A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- acid
- crystalline form
- methyl
- ibandronic
- Prior art date
Links
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 title claims abstract description 89
- 229960005236 ibandronic acid Drugs 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- 238000006243 chemical reaction Methods 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 42
- 239000002904 solvent Substances 0.000 claims description 40
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- UOIWOHLIGKIYFE-UHFFFAOYSA-N n-methylpentan-1-amine Chemical compound CCCCCNC UOIWOHLIGKIYFE-UHFFFAOYSA-N 0.000 claims description 30
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 23
- VBDRTGFACFYFCT-UHFFFAOYSA-M sodium;hydroxy-[(1r)-1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate;hydrate Chemical compound O.[Na+].CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)([O-])=O VBDRTGFACFYFCT-UHFFFAOYSA-M 0.000 claims description 23
- 239000003085 diluting agent Substances 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 239000003638 chemical reducing agent Substances 0.000 claims description 17
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 17
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims description 17
- XKEKKGKDCHCOSA-UHFFFAOYSA-N n-methylpentanamide Chemical compound CCCCC(=O)NC XKEKKGKDCHCOSA-UHFFFAOYSA-N 0.000 claims description 15
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 12
- 238000001953 recrystallisation Methods 0.000 claims description 11
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims description 11
- YDWXRULMHQZBEX-UHFFFAOYSA-N 3-[methyl(pentyl)amino]propanoic acid;hydrochloride Chemical compound Cl.CCCCCN(C)CCC(O)=O YDWXRULMHQZBEX-UHFFFAOYSA-N 0.000 claims description 10
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- HNBDRPTVWVGKBR-UHFFFAOYSA-N methyl pentanoate Chemical compound CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 claims description 8
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 238000000862 absorption spectrum Methods 0.000 claims description 7
- 238000009833 condensation Methods 0.000 claims description 7
- 230000005494 condensation Effects 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- YWSCUVIPKSJBRU-UHFFFAOYSA-N 3-[methyl(pentyl)azaniumyl]propanoate Chemical compound CCCCCN(C)CCC(O)=O YWSCUVIPKSJBRU-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001767 cationic compounds Chemical group 0.000 claims description 4
- 150000002892 organic cations Chemical group 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 229940005605 valeric acid Drugs 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000032050 esterification Effects 0.000 claims description 3
- 238000005886 esterification reaction Methods 0.000 claims description 3
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 3
- ZWKFEVVFVAGPDE-UHFFFAOYSA-N methyl 3-[methyl(pentyl)amino]propanoate Chemical compound CCCCCN(C)CCC(=O)OC ZWKFEVVFVAGPDE-UHFFFAOYSA-N 0.000 claims description 3
- 150000007524 organic acids Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 50
- 239000007787 solid Substances 0.000 description 47
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000010410 layer Substances 0.000 description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000004090 dissolution Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 239000012429 reaction media Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 150000002825 nitriles Chemical class 0.000 description 9
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- NPDACUSDTOMAMK-UHFFFAOYSA-N 4-Chlorotoluene Chemical group CC1=CC=C(Cl)C=C1 NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- -1 alkyl sulfonic acids Chemical class 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 239000012296 anti-solvent Substances 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000005662 Paraffin oil Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 3
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000004645 aluminates Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229940117389 dichlorobenzene Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LJCNRYVRMXRIQR-UHFFFAOYSA-L potassium sodium tartrate Chemical compound [Na+].[K+].[O-]C(=O)C(O)C(O)C([O-])=O LJCNRYVRMXRIQR-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- DRPKUPBGKFMTRM-UHFFFAOYSA-N (2-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid Chemical compound CC(N)C(O)(P(O)(O)=O)P(O)(O)=O DRPKUPBGKFMTRM-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical group C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- 0 CCCCCN(C)CCC(O)(P(*)(O)=O)P(O)(O)=O Chemical compound CCCCCN(C)CCC(O)(P(*)(O)=O)P(O)(O)=O 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037848 Metastatic bone disease Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 229940028101 boniva Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- MVPPADPHJFYWMZ-IDEBNGHGSA-N chlorobenzene Chemical group Cl[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 MVPPADPHJFYWMZ-IDEBNGHGSA-N 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229950004969 olpadronic acid Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
Definitions
- the present invention relates to a crystalline form of ibandronic acid and a process for the preparation thereof.
- the present invention also relates to crystalline Form A of ibandronic acid and a process for its preparation, and also a process for the preparation of substantially pure ibandronate sodium Form A.
- Ibandronic acid is used as an intermediate for the preparation of ibandronate sodium.
- Ibandronate sodium is chemically named as 3-( ⁇ /-methyl- ⁇ /-pentyl) quine-1- hydroxypropane-1 ,1-diphosphonic acid, monosodium salt, monohydrate (hereinafter referred to as "ibandronate sodium”) and has structural Formula II.
- the monosodium salt of ibandronic acid is useful in the treatment of bone disorders such as hypocalcaemia of malignance, osteolysis, Paget's disease, osteoporosis and metastatic bone diseases and is available in the market under the trade name BONIVA as an ampoule with 1 ml concentrate for solution for infusion containing 1.125 mg of ibandronic acid monosodium salt monohydrate, corresponding to 1 mg of ibandronic acid in the form of tablets.
- Fig. 1 is a schematic representation of an embodiment of a process for the preparation of ibandronic acid and its salts.
- Fig. 3 is quantification curve to show 2% of ibandronate sodium monohydrate Form A in ibandronate sodium monohydrate Form B.
- Fig. 6 is quantification curve to show 1 % of ibandronate sodium monohydrate Form B in Form A.
- Fig. 7 is an X-ray powder diffraction pattern of ibandronate sodium monohydrate Form A prepared as in Example 13.
- Fig. 8 is quantification curve to show the percentage of ibandronate sodium monohydrate Form B in Form A prepared as in Example 13.
- Fig. 9 is an XRPD pattern of a combination of ibandronate sodium monohydrate Form A and Form B in a specific weight ratio of 45:55, prepared according to Example 15.
- Fig. 11 is the schematic representation of the preparation of the compound of Formula II.
- Fig. 12 is the schematic representation of the preparation of the compound of Formula Vl.
- Fig. 13 is an X-ray powder diffraction (XRPD) pattern of ibandronoic acid crystalline Form A.
- Fig. 14 is an infrared (IR) absorption spectrum of ibandronic acid crystalline Form A.
- the process for the preparation of ibandronic acid and its salts comprises: a) esterfication of valeric acid of Formula Ma, followed by condensation with methylamine to give N-methylpentanamide of Formula IVa.
- Suitable temperatures for conducting the reaction range from about -10 0 C to about 50 0 C, or from about 10 0 C to about 30 0 C.
- the alcohol used is methanol, and the corresponding ester formed is methyl pentanoate of Formula Ilia.
- Suitable solvents which can be used for the condensation of methylamine with the intermediate ester include, but are not limited to Ci-C ⁇ straight chain, branched, cyclic, or chlorinated hydrocarbons; aromatic hydrocarbons such as toluene, xylene; nitriles such as acetonitrile, propionitrile; ethers such as tetrahydrofuran and the like or mixtures thereof.
- methylamine is used in the form of its aqueous solution.
- the reaction can also be conducted without using any additional solvent and using the solution of methylamine as the solvent.
- Suitable temperatures for conducting the reaction range from about -15 to about 50 °C, or about 10 to 40 0 C, or about 25 to about 35 0 C.
- the intermediate compound of Formula IVa in step (b) may or may not be isolated. The same can be converted in situ, if desired, to the compound of Formula Va in step (b).
- Suitable reducing agents which can be used at the desired temperature ranges include, but are not limited to, sodium bis(2-methoxyethoxy) aluminum hydride (Vitride), lithium aluminium hydride, sodium borohydride/acetic acid, diisobutyl aluminium hydride (DIBAL H) and the like.
- the reduction reaction is sensitive to moisture, hence the moisture content of the individual components and the reaction medium before adding the reducing agent should be less than 1% w/w.
- the molar ratio of the reducing agent to the starting N-methylpentanamide of Formula IVa is from about 0.5 to about 10, or from about 1.0 to about 5.0 moles.
- Suitable solvents which can be used for the reaction include, but are not limited to Ci-C ⁇ straight chain or branched chain chlorohydrocarbons including dichloromethane, ethylene dichloride, chloroform, and carbon tetrachloride; chlorinated aromatics such as chlorobenzene, dichlorobenzene, and the like; hydrocarbons such as C 1 -C- 6 straight chain, branched or cyclic hydrocarbons; aromatic hydrocarbons such as toluene, xylene; nitriles such as acetonitrile, propionitrile; ethers such as tetrahydrofuran and the like or mixtures thereof.
- the intermediate compound of Formula Va in step (b) may or may not be isolated. The same can be converted in situ, if desired, to the compound of Formula Via in step c).
- Suitable solvents which can be used for the reaction include, but are not limited to, C 1 -C 6 straight chain or branched chlorohydrocarbons, hydrocarbons, aromatic hydrocarbons such as toluene, xylene, and the like; nitriles such as acetonitrile, propionitrile and the like; polar solvents like water; or mixtures thereof.
- the reaction may optionally be conducted in the absence of any additional solvent, when the reagent methyl acrylate acts the medium for reaction.
- Suitable temperatures for conducting the reaction can range from about -15 to 50 0 C, or about 10 to 40 0 C, or about 25 to 35 0 C.
- the intermediate compound of Formula Via may or may not be isolated and may be directly hydrolyzed in-situ if desired, to the compound of Formula Vila.
- the hydrolysis can be done either in the acidic conditions or basic conditions using suitable acids or bases as required.
- suitable acids which can be used for acidic hydrolysis include, but are not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, para-toluene sulfonic acid and the like; organic acids such as oxalic acid, acetic acid, tartaric acid, formic acid and the like.
- Suitable bases which can be used for basic hydrolysis include, but are not limited to sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium tertiary butoxide, potassium tertiary butoxide, sodium secondary butoxide, sodium tertiary butoxide and the like; alkali metal hydroxides comprises sodium hydroxide, potassium hydroxide, lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, lithium carbonate and the like; alkali metal hydrides comprises sodium hydride and the like.
- the product can be isolated as the acid addition salt or as the base addition salt based on the reagent selected for hydrolysis.
- the salt obtained can be further purified by recrystallization or slurry in a suitable solvent. Recrystallization involves providing a solution of the intermediate in a suitable solvent and then crystallizing the solid from the solution.
- Suitable organic solvents which can be used for recrystallization or slurry include but are not limited to alcoholic solvents such as methanol, ethanol, isopropyl alcohol, n- propanol, and the like; halogenated solvents such as dichloromethane, 1 ,2- dichloroethane, chloroform, carbon tetrachloride and the like; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, t-butyl acetate and the like; ether solvents such as diethyl ether.dimethyl ether, di-isopropyl ether, methyl tertiary-butyl ether, tetrahydrofuran, 1 ,4-dioxane and the like; nitrile solvents such as acetonitrile, propionitrile and the like; and mixtures thereof in various proportions.
- alcoholic solvents such as methanol,
- the compound obtained can be further dried suitably using a tray dryer, vacuum oven, air oven, fluidized bed drier, spin flash dryer, flash dryer and the like.
- the drying can be carried out at temperatures of about 35 0 C to about 70 0 C.
- the drying can be carried out for any desired time periods to achieve the desired product purity, times from about 1 to 20 hours, or longer, frequently being sufficient.
- the hydrolysis is carried out using hydrochloric acid and the acid addition salt formed is the hydrochloride salt of Formula Villa.
- Suitable phosphonating agents which can be used for the reaction include, but are not limited to, phosphorous acid in combination with any one of phosphorous trichloride, phosphorous pentachloride, phosphorous oxy trichloride, phosphorous tribromide, phosphorous pentabromide, phosphorous oxybromide and the like.
- Diluent is an inert substance used to dilute the reaction medium.
- Suitable diluents which can be used include, but are not limited to, hydrocarbons such as Ci to C ⁇ straight chain, branched, or cyclic hydrocarbons; aromatic hydrocarbons such as N- pentane, n-hexane, n-heptane, cyclohexane, toluene, 4-chloro toluene, xylene, and the like; nitriles such as acetonitrile, propionitrile, and the like.
- chlorinated hydrocarbon solvents such as Ci to Ce straight chain or branched chain chlorohydrocarbons including dichloromethane, ethylene dichloride, chloroform, and carbon tetrachloride; chlorinated aromatics such as chlorobenzene, dichlorobenzene, and the like; ethers such as tetrahydrofuran; alkyl sulfonic acids such as methanesulfonic acid, toluene sulfonic acid, paraffin oil, pyridine, 2-methyl pyrrolidone, and the like can be used in combination with diluents such as methanesulfonic acid, triphenyl phosphine, pyridine, paraffin oil, morpholine and the like.
- chlorinated hydrocarbon solvents such as Ci to Ce straight chain or branched chain chlorohydrocarbons including dichloromethane, ethylene dichloride, chloroform, and carbon tetrachloride
- chlorinated aromatics such as chlor
- Suitable temperatures for conducting the reaction range from about 20 to about 200 0 C, or from about 20 to about 100 °C.
- the diluent used for the preparation of ibandronic acid and its salts is a combination of chlorobenzene and methane sulfonic acid
- the phosphonating agent is a combination of phosphorus acid and phosphorous trichloride.
- the mole ratio of methanesulfonic acid to the starting material 3-(N-methyl-N- pentylamino) propanoic acid or its salt of Formula Vila may range from about 0.8 to 1 moles per mole of the starting material. It is important to maintain the mole ratio within the said limits as a mole ratio less than or more than the given range effects the yield of the product since the excess of methanesulfonic acid if present in the reaction medium reacts with the phosphorus trichloride making it unavailable for the desired reaction.
- the product ibandronic acid which is formed in insoluble in chlorobenzene and hence separates as a gum when it is formed in the reaction medium suitably methanesulfonic acid is added slowly to the reaction medium such that the exothermicity caused during the addition can be controlled and the product formed is dissolved.
- the pH of the reaction medium containing ibandronic acid is adjusted to about 1.0 to about 1.8; and when a dibasic salt is proposed to be formed the pH of the reaction medium is adjusted to about 3.0 to about 5.0.
- Suitable bases which can be used for salt formation include, but are not limited to alkali metal alkoxides such as potassium alkoxide, sodium methoxide; alkali metal hydroxides such as sodium hydroxide, potassium hydroxide; alkali metal carbonates such as sodium carbonate, sodium bicarbonate; amines such as tertiarybutylamine, dicyclohexylamine and the like.
- the base used is sodium hydroxide and the salt formed is ibandronate sodium.
- lbandronate sodium thus formed may optionally be further purified by recrystallization or slurry in a suitable solvent. Recrystallization involves providing a solution of ibandronate sodium in a suitable solvent and then crystallizing the solid from the solution.
- the concentration of ibandronate sodium in the solvent can range from about 0.1 to about 10 g/ml or more.
- a solution can be prepared at an elevated temperature if desired to achieve a desired concentration. Any temperature is acceptable for the dissolution as long as a clear solution of the ibandronate sodium is obtained and is not detrimental to the drug substance chemically or physically.
- the solution may be brought down to room temperature for further processing if required or an elevated temperature may be used. A higher temperature will allow the precipitation from solutions with higher concentrations of ibandronate sodium resulting in better economies of manufacture.
- the compound obtained can be further dried suitably using a tray dryer, vacuum oven, air oven, fluidized bed drier, spin flash dryer, flash dryer and the like.
- the drying can be carried out at temperatures of about 35 °C to about 70 °C.
- the drying can be carried out for any desired time periods to achieve the desired product purity, times from about 1 to 20 hours, or longer, frequently being sufficient.
- the present invention provides a process for the preparation of crystalline Form A of ibandronic acid, comprising the steps of: i) reacting N-methyl-N-pentyl amine propionic acid of Formula IV
- Suitable organic solvents for isolation include but are not limited to: alcohols such as methanol, ethanol, and isopropanol, butanol and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; esters such as ethyl acetate, n- propyl acetate, n-butyl acetate, tertiary-butyl acetate and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, ethylene dichloride, chloroform and the like; aprotic polar solvents such as N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), N, N- dimethylacetamide (DMA) and the like; or mixtures thereof.
- the organic solvent is chlorobenzene as solvent.
- the reaction temperature for conversion of the compound of Formula IV to the compound of Formula I in step (i) can range from about 0 0 C to about 60 0 C, or up to the reflux temperature of the solvent used.
- Organic solvents used for purification include but are not limited to any solvent or mixture of solvents in which ibandronic acid is soluble, for example alcohols such as methanol, ethanol, and isopropanol, butanol and the like.
- Step (iv) recovering the desired crystalline Form A of ibandronic acid.
- Step (iv) can be carried out by using techniques, such as centrifugation, decantation, gravity filtration, vacuum filtration or other techniques known to one skilled in the art for the separation of solids.
- the wet solid isolated in step (iii) may be dried by using techniques, such as for example fluid bed drying (FBD), aerial drying, oven drying or other techniques known to one skilled in the art.
- the drying can be conducted at temperatures of about 0 0 C to about 30 0 C or about 25 0 C to about 30 °C with or without application of a vacuum. Drying can be carried out under inert conditions.
- the present invention provides an improved process for the preparation of substantially pure crystalline Form A of ibandronic acid comprising the step of recrystallisation of crude ibandronic acid using suitable organic solvent(s) for example alcohols such as methanol, ethanol, and isopropanol, butanol and the like or mixtures thereof to afford the desired substantially pure crystalline Form A Ibandronic acid.
- suitable organic solvent(s) for example alcohols such as methanol, ethanol, and isopropanol, butanol and the like or mixtures thereof to afford the desired substantially pure crystalline Form A Ibandronic acid.
- the process for the preparation of substantially pure ibandronate sodium monohydrate crystalline Form A, substantially pure ibandronate sodium monohydrate crystalline Form B and a mixture of Form A and Form B comprises: a) providing a solution of ibandronate sodium; b) adding an antisolvent to the solution obtained in step a); c) isolating the separated solid.
- the solution of ibandronate sodium may be obtained by dissolving the ibandronate sodium in a suitable solvent, or such a solution may be obtained directly from a reaction in which ibandronate sodium is formed.
- any form of ibandronate sodium such as the crystalline or amorphous form, including any salts, solvates and hydrates may be utilized for preparing the solution.
- Suitable solvents useful in the preparation of the monohydrate of ibandronate sodium include water alone or in combination with an organic solvent, such as for example ketones like acetone, propanone; acetonitrile, and the like; and mixtures thereof.
- the quantity of solvent used for dissolution is critical in determining the final polymorphic form obtained from the process. When the quantity of solvent is less than 1.6 times to the weight of ibandronate sodium taken, the resulting polymorphic form is ibandronate sodium monohydrate Form A, and when the quantity is more than about 1.6 or more than about 2.0 times, the resulting polymorphic form is ibandronate sodium polymorphic Form B.
- Any temperature below 200 °C may be used for dissolution as long as a clear solution is obtained.
- Step b) adding an antisolvent to the solution obtained in step a).
- a solvent or a mixture of solvents may be added to the solution obtained in step a) to initialize crystallization.
- Suitable solvents which can be used as anti-solvents include, but are not limited to water, ketonic solvents like acetone, ethyl methyl ketone, and the like or mixtures thereof.
- the temperature for addition of the anti-solvent may range from about 40 °C to about 70 °C or from about 50 °C to about 60 °C.
- the cooling of the solution may be achieved by simple radiation cooling under atmospheric conditions, accompanied by stirring, or through the use of controlled cooling mechanisms such as for example circulation of cooling media in jacket vessels and the like.
- controlled cooling mechanisms such as for example circulation of cooling media in jacket vessels and the like.
- Recovery can be performed by any means including, but not limited to, filtration, centrifugation, and decanting.
- the crystalline form may be recovered from any composition containing the crystalline form and the solvent or solvents including but not limited to a suspension, solution, slurry, and emulsion.
- Form A of ibandronate sodium monohydrate is mixed with Form B in any ratio from about 0.1 to 99% w/w with respect to the other form.
- Any form of mixing may be utilized to ensure complete homogeneity of one form in the other. Such forms of mixing could include trituration, blending using different blenders and the like and are within the scope of understanding of a person skilled in the art of processing pharmaceutical powders.
- the individual crystalline forms or the final mixture may also be subjected to pulverization to reduce the particle size. The particle size and distribution to be used will be determined by the composition into which the mixture is to be incorporated, rates of dissolution and the like and will be within the scope of understanding of a pharmaceutical scientist.
- the mixture is a 45 + 5 to 45 + 5 mixture of Form A to Form B, and the mixing is done by stirring the required weights of Form A and Form B in a flask at an RPM of about 25 to about 30.
- present invention provides an improved process for the synthesis of ibandronate sodium of Formula II,
- Suitable diluents that may be used for the reaction includes but are not limited to: methane sulfonic acid, paraffin oil, pyridine, 2-methyl pyrrolidone, and the like; or mixtures thereof, or their combination with water in various proportions.
- the diluent is methane sulfonic acid.
- Suitable organic solvents used for isolation include but are not limited to: alcohols such as methanol, ethanol, and isopropanol, butanol and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, tertiary-butyl acetate and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, ethylene dichloride, chloroform and the like; aprotic polar solvents such as N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), N 1 N- dimethylacetamide (DMA) and the like; or mixtures thereof, or their combination with water in various proportions.
- alcohols such as methanol, ethanol, and is
- Suitable reducing agents include but are not limited to lithium aluminium hydride, Diisobutylaluminium hydride (DIBAL-H), Sodium Dihydro-bis-(2-Methoxyethoxy) Aluminate (vitride), Sodium borohydride in combination with acetic acid, sodium cyano borohydride and the like.
- the reducing agent is vitride.
- Temperatures for conversion of compound of Formula V to the compound of Formula Vl can range from about 0 0 C to about 90 0 C.
- Still another aspect of the present invention provides crystalline Form A of ibandronic acid, and a process for its preparation.
- the crystalline Form A of ibandronic acid has an XRD pattern substantially in accordance with Figure 4, which was measured on a Bruker Axe, D8 Advance Powder X-ray Diffractometer with a Cu K alpha-1 radiation source.
- the crystalline Form A of ibandronic acid obtained by the above process is characterized by an X-ray powder diffraction pattern using Cu K ⁇ -1 radiation with peaks at approximately: 5, 5.9, 7.3, 8.2, 11 , 12.2, 13.9, 14.6, 18.7, 21.2, 22.8, 24.6, 30.7, ⁇ 0.2 degrees 2 theta.
- IR infrared
- Crystalline Form A ibandronic acid is characterized by an infrared absorption spectrum in potassium bromide comprising peaks at about 523.13, 576.98, 672.03, 663.29, 641.13, 933.64, 1054.19, 1152.13, 1381.93, 1473.01 , 1641.95, 2309.79, 2759.58, 2873.35, 2937.52, 2960.91 , and 3089.95 ⁇ 5 cm-1.
- Crystalline Form A ibandronic acid is also characterized by its infrared absorption spectrum in potassium bromide substantially in accordance with the spectrum of Fig. 14. The process for its preparation comprises purification of the crude acid obtained according to the process of the present invention or any processes described in the prior art.
- Organic solvents which can be used include but are not limited to any solvent or mixture of solvents in which ibandronic acid is soluble, for example alcohols such as methanol, ethanol, and isopropanol, butanol and the like or mixtures thereof.
- lbandronate salts prepared according to the process of the present invention have a D 90 less than about 200 ⁇ m.
- D-io, D 50 and D 90 values are useful ways for indicating a particle size distribution.
- Dgo refers to the value for the particle size for which at least 90 volume percent of the particles have a size smaller than the value.
- D 50 and Di 0 refer to the values for the particle size for which 50 volume percent, and 10 volume percent, of the particles have a size smaller than the value.
- Methods for determining Di 0 , D 50 and D 90 include laser diffraction, such as using Malvern Instruments Ltd. (of Malvern, Worcestershire, United Kingdom) equipment.
- Ibandronic acid and its pharmaceutically acceptable salts prepared according to the present invention have a mean particle size of less than about 100 ⁇ m, D1 0 less than 20 ⁇ m or less than 50 ⁇ m, D 50 less than 50 ⁇ m or less than 100 ⁇ m, and D9 0 less than 100 ⁇ m or less than 200 ⁇ m. There is no specific lower limit for any of the D values.
- the processes of present invention are simple, cost effective, ecofriendly, reproducible, scalable, robust to produce the desired crystalline Form A of ibandronic acid, which is free flowing and directly compressible into stable formulations.
- Still more another aspect of the present invention provides a pharmaceutical composition comprising pure ibandronic acid or its pharmaceutically acceptable salts along with one or more pharmaceutically acceptable carriers, excipients or diluents.
- the pharmaceutical composition may be formulated as: solid oral dosage forms such as, but not limited to, powders, granules, pellets, tablets, and capsules; liquid oral dosage forms such as but not limited to syrups, suspensions, dispersions, and emulsions; and injectable preparations such as, but not limited to, solutions, dispersions, and freeze dried compositions.
- Formulations may be in the form of immediate release, delayed release or modified release.
- immediate release compositions may be conventional, dispersible, chewable, mouth dissolving, or flash melt preparations, and modified release compositions that may comprise hydrophilic or hydrophobic, or combinations of hydrophilic and hydrophobic, release rate controlling substances to form matrix or reservoir or combination of matrix and reservoir systems.
- compositions may be prepared by direct blending, dry granulation or wet granulation or by extrusion and spheronization.
- Compositions may be presented as uncoated, film coated, sugar coated, powder coated, enteric coated or modified release coated.
- Compositions of the present invention may further comprise one or more pharmaceutically acceptable excipients.
- compositions of present invention ibandronic acid or its pharmaceutically acceptable salts is a useful active ingredient in the range of 0.5 mg to 500 mg, or 1 mg to 250 mg, per dosage form unit.
- N-methyl-N-pentyl propionic acid of Formula IV (50 g) was charged into a 4-neck round bottom flask containing chlorobenzene (350 ml), and phosphorous acid and heated to about 80 0 C to about 85 0 C.
- Phosphorous trichloride (52 ml) was added slowly over a period of about 20-30 minutes and the reaction mass was stirred for about 4 to about 5 hours to a temperature of about 85 0 C to about 90 0 C.
- the reaction mass was cooled to about 60 0 C -65 0 C followed and water (250 ml) was slowly added over a period of about 30 to about 45 minutes.
- the separated solid was filtered through celite and the organic and aqueous layers were separated.
- the crystalline form A of ibandronic acid is characterized by an infrared absorption spectrum in potassium bromide comprising peaks at about 523.13, 576.98, 672.03, 663.29, 641.13, 933.64, 1054.19, 1152.13, 1381.93, 1473.01 , 1641.95, 2309.79, 2759.58, 2873.35, 2937.52, 2960.91 , and 3089.95 ⁇ 5 cm-1.
- Crystalline Form A ibandronic acid is also characterized by its infrared absorption spectrum in potassium bromide substantially in accordance with the spectrum of Fig. 14.
- EXAMPLE -2 PROCESS FOR THE PREPARATION OF IBANDRONATE SODIUM (FORMULA II)
- 3-(N-methyl-N-pentylamino) propanoic acid hydrochloride of Formula III (20 mg) was charged into a round bottom flask containing chlorobenzene (140 ml) and phosphorous acid (15.6 g). The contents were heated to about 75 0 C to about 80 0 C and phosphorous trichloride (20.8 ml) was added slowly for about 20 to about 30 minutes, followed by addition of methane sulfonic acid (10 ml) for a period of about 20 to about 30 minutes. The reaction mass was stirred for about 3 to about 4 hours at a temperature of about 90 0 C to about 100 0 C followed by cooling to about 50 0 C to about 60 0 C.
- the above-obtained wet solid (28 g) was charged into a round bottom flask containing water (56 ml) and heated to about 60 0 C to about 70 0 C and maintained for about 30 to about 45 minutes followed by cooling the reaction mass to about 25 0 C to about 30 0 C. Methanol (112 ml) was added in to the reaction mass and stirred for about 30 to about 45 minutes. The separated solid was filtered and the solid was washed with methanol (20 ml) and kept for sucking for about 30 to about 45 minutes. The filtered solid was charged into a round bottom flask containing water (50 ml) and the contents were heated to about 65 0 C to about 70 0 C for about 45 to about 60 minutes.
- Acetone 200 ml was added into the reaction mass and stirred for about 20 to about 30 minutes.
- the separated solid was filtered and the solid was washed with acetone (50 ml) and kept for sucking for about 30 to about 45 minutes.
- the solid obtained was dried to about 45 0 C to about 50 0 C for about 3 to about 4 hours to afford 16 gm of title compound as a solid with purity by HPLC 99.76%.
- N-methylpentanamide of Formula V (40 g) was charged into a round bottom flask containing toluene (200 ml) followed by stirring for about 5 to about 10 minutes. The aqueous layer and toluene layer were separated and kept aside. Sodium Dihydro-bis- (2-Methoxyethoxy) Aluminate (vitride) (210 ml) and toluene (200 ml) were charged into a clean and dry round bottom flask followed by stirring for about 5 to about 10 minutes. The above-obtained N-methylpentanamide dissolved in toluene was added drop wise slowly over about 45 to about 60 minutes at a temperature of about 25 °C to about 30 0 C.
- the resultant reaction mass was stirred for about 7 to about 8 hours at about 25 0 C to about 30 0 C followed by cooling to about 5 0 C to about 10 0 C.
- Sodium potassium tartarate (120 g) was dissolved in water (800 ml) and added drop wise slowly over a period of about 30 to about 45 minutes at about 0 0 C to about 10 0 C followed by stirring for about 10 to about 15 minutes.
- the organic and aqueous layers were separated and the aqueous layer was extracted with toluene (120 ml) followed by separation of the organic and the aqueous layers. Both the organic layers were combined and the total organic layer was washed with water (2x80 ml) followed by separation of the organic and the aqueous layers.
- the organic layer obtained by a process similar to one described in Example 6 was taken (containing 21 g of N-methylpentylamine). 69 ml of methyl acrylate was added to it and maintained at about 28 °C for about 15 hours. Reaction completion was checked using thin layer chromatography. After the reaction was completed, the organic layer was proceeded to the next stage. Purity by GC: 92.45%.
- the reaction mass was cooled to about 27 0 C and filtered through a flux calcined diatomaceous earth (Hyflow) bed.
- the aqueous layer was separated from the filtrate and heated to about 95 0 C in another flask.
- the aqueous layer was stirred at about 95 °C for about 19 hours and then cooled to about 5 0 C.
- 140 ml of methanol was then added and the contents were stirred for about 20 minutes.
- 2.5 g of sodium hydroxide was charged and stirred for about 5 hours and 25 minutes at about 3 0 C.
- Another 1.0 g of sodium hydroxide was added and stirred for about 4 hours and 20 minutes at about 3 0 C.
- the separated solid was filtered and washed with 20 ml of methanol. The solid was dried at about 55 0 C for about 6 hours to afford 7.0 g of the title compound as crystalline solid.
- the contents were heated again to about 75 °C and stirred for about 15 minutes.
- the reaction mass was filtered through a flux calcined diatomaceous earth (Hyflow) bed and aqueous layer separated from the filtrate was heated to about 95 °C in another flask.
- the aqueous layer was stirred at about 95 °C for about 19 hours and then cooled to about 5 0 C.
- 100 ml of ethanol was added and the contents were stirred for about 20 minutes. 5.8 g of sodium hydroxide was added and stirred for about 8 hours at about 4 °C.
- the solid was separated, filtered and washed with 50 ml of ethanol. The solid was dried at about 54 0 C for about 6 hours 30 minutes to afford 4.8 g of the title compound as crystalline solid.
- the wet compound was again taken into another round bottom flask and 168 ml of water was added to it.
- the mixture was heated to about 70 °C and about 80 ml of water was distilled off.
- the reaction mass was again heated to about 76 0 C and 84 ml of water was added to it.
- the reaction mass was cooled to about 30 0 C and 500 ml of acetone was added to it.
- the reaction mass was stirred at about 30 0 C for about 1 hour.
- the separated solid was filtered and washed with 50 ml of acetone.
- the wet solid was taken into another round bottom flask and 272 ml of water was added t it.
- ibandronate sodium 50 g was taken and 61.6 ml of water was added to it. The mixture was heated to about 90 °C and checked for clear dissolution. After a clear dissolution was obtained, the solution was filtered under hot condition and the filtrate was cooled to about 50 0 C. A mixture of 250 ml of acetone and 50 ml of water was added to the above solution at about 50 0 C. The reaction mass was then cooled to about 30 0 C and maintained for about 6 hours. The separated solid was filtered and washed with 83.3 ml of acetone. The wet solid was dried at about 60 0 C for about 12 hours to yield 47.5 g of the title compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates crystalline Form A of Ibandronic acid having Formula (I) and a process for the preparation thereof.
Description
CRYSTALLINE FORM A OF IBANDRONIC ACID AND PROCESS FOR THE PREPARATION
FIELD
The present invention relates to a crystalline form of ibandronic acid and a process for the preparation thereof. The present invention also relates to crystalline Form A of ibandronic acid and a process for its preparation, and also a process for the preparation of substantially pure ibandronate sodium Form A.
BACKGROUND
Ibandronic acid is chemically named as 3-(Λ/-methyl-Λ/-pentyl) amino-1- hydroxypropane-1 ,1-diphosphonic acid (herein after referred to as "ibandronic acid") and has structural Formula I.
Formula I
Ibandronic acid is used as an intermediate for the preparation of ibandronate sodium. Ibandronate sodium is chemically named as 3-(Λ/-methyl-Λ/-pentyl) quine-1- hydroxypropane-1 ,1-diphosphonic acid, monosodium salt, monohydrate (hereinafter referred to as "ibandronate sodium") and has structural Formula II.
Formula Il
The monosodium salt of ibandronic acid is useful in the treatment of bone disorders such as hypocalcaemia of malignance, osteolysis, Paget's disease,
osteoporosis and metastatic bone diseases and is available in the market under the trade name BONIVA as an ampoule with 1 ml concentrate for solution for infusion containing 1.125 mg of ibandronic acid monosodium salt monohydrate, corresponding to 1 mg of ibandronic acid in the form of tablets.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a schematic representation of an embodiment of a process for the preparation of ibandronic acid and its salts.
Fig. 2 is an X-ray powder diffraction pattern of ibandronic acid Form A prepared as in Example 12.
Fig. 3 is quantification curve to show 2% of ibandronate sodium monohydrate Form A in ibandronate sodium monohydrate Form B.
Fig. 4 is an X-ray powder diffraction pattern of ibandronate sodium monohydrate Form B prepared as in Example 11.
Fig. 5 is quantification curve to show the percentage of Form A in ibandronate sodium monohydrate Form B prepared as in Example 11.
Fig. 6 is quantification curve to show 1 % of ibandronate sodium monohydrate Form B in Form A.
Fig. 7 is an X-ray powder diffraction pattern of ibandronate sodium monohydrate Form A prepared as in Example 13.
Fig. 8 is quantification curve to show the percentage of ibandronate sodium monohydrate Form B in Form A prepared as in Example 13.
Fig. 9 is an XRPD pattern of a combination of ibandronate sodium monohydrate Form A and Form B in a specific weight ratio of 45:55, prepared according to Example 15.
Fig. 10 is the schematic representation of the preparation of the compound of Formula I.
Fig. 11 is the schematic representation of the preparation of the compound of Formula II.
Fig. 12 is the schematic representation of the preparation of the compound of Formula Vl.
Fig. 13 is an X-ray powder diffraction (XRPD) pattern of ibandronoic acid crystalline Form A.
Fig. 14 is an infrared (IR) absorption spectrum of ibandronic acid crystalline Form A.
DETAILED DESCRIPTION
The crystalline form of the present application is designated as crystalline Form A for convenience.
In one embodiment, the present invention provides a crystalline Form A of ibandronic acid having Formula I.
In an embodiment, the process for the preparation of ibandronic acid and its salts comprises: a) esterfication of valeric acid of Formula Ma, followed by condensation with methylamine to give N-methylpentanamide of Formula IVa.
Formula Ha Formula IVa b) reduction of N-methylpentanamide of Formula IVa with a suitable reducing agent to afford N-methyl pentylamine of Formula Va;
Formula Va c) condensation of N-methyl pentylamine of Formula Va with methyl acrylate to afford methyl 3-(N-methyl-N-pentylamino)propanoate of Formula Via followed by its hydrolysis to give its salt of Formula Vila;
Formula Via Formula Vila where X is an inorganic or organic acid, or an inorganic or organic cation. d) reaction of 3-(N-methyl-N-pentylamino) propanoic acid or its salt of Formula Vila with phosphonating agent in a suitable diluent to give ibandronic acid of Formula I, which can subsequently be converted into its salt of Formula IXa.
Formula IXa where X' is an inorganic or organic cation.
Step a) esterfication of valeric acid of Formula Ma.
Esterification can be carried out in the presence of an alcohol and a strong acid. Suitable alcohols which can be used include, but are not limited to methanol, ethanol, propanol, isobutyl alcohol, isopropanol, and the like to form the corresponding esters. Suitable strong acids which can be used include, but are not limited to sulfuric acid, acetic acid, hydrochloric acid, nitric acid, phosphoric acid and the like.
Suitable temperatures for conducting the reaction range from about -10 0C to about 50 0C, or from about 10 0C to about 30 0C.
In an embodiment, the alcohol used is methanol, and the corresponding ester formed is methyl pentanoate of Formula Ilia.
Formula Ilia
Suitable solvents which can be used for the condensation of methylamine with the intermediate ester include, but are not limited to Ci-Cβ straight chain, branched, cyclic, or chlorinated hydrocarbons; aromatic hydrocarbons such as toluene, xylene; nitriles such as acetonitrile, propionitrile; ethers such as tetrahydrofuran and the like or mixtures thereof.
Suitably, methylamine is used in the form of its aqueous solution. The reaction can also be conducted without using any additional solvent and using the solution of methylamine as the solvent.
Suitable temperatures for conducting the reaction range from about -15 to about 50 °C, or about 10 to 40 0C, or about 25 to about 35 0C.
The intermediate compound of Formula IVa in step (b) may or may not be isolated. The same can be converted in situ, if desired, to the compound of Formula Va in step (b).
Step (b) reduction of N-methylpentanamide of Formula IVa.
The reducing agent which is to be used in this stage is to be selected carefully, as the product formed in this stage is highly volatile. Most of the reducing agents used in the art require the reaction to be conducted at very high temperatures of the range of more than 70 °C. It is desirable to select a reducing agent which can be used at lower temperatures of the range of below 50 0C to avoid degradation of the product due to high temperatures.
Suitable reducing agents which can be used at the desired temperature ranges include, but are not limited to, sodium bis(2-methoxyethoxy) aluminum hydride (Vitride), lithium aluminium hydride, sodium borohydride/acetic acid, diisobutyl aluminium hydride (DIBAL H) and the like. The reduction reaction is sensitive to moisture, hence the
moisture content of the individual components and the reaction medium before adding the reducing agent should be less than 1% w/w.
The reaction medium containing the starting material and the solvent is made free of moisture suitably by using techniques such as treatment with hydrating agents like sodium sulfate, magnesium sulfate, molecular sieves and the like, azeotropic distillation of the reaction medium or other techniques known to one skilled in the art.
The molar ratio of the reducing agent to the starting N-methylpentanamide of Formula IVa is from about 0.5 to about 10, or from about 1.0 to about 5.0 moles.
Suitable solvents which can be used for the reaction include, but are not limited to Ci-Cβ straight chain or branched chain chlorohydrocarbons including dichloromethane, ethylene dichloride, chloroform, and carbon tetrachloride; chlorinated aromatics such as chlorobenzene, dichlorobenzene, and the like; hydrocarbons such as C1-C-6 straight chain, branched or cyclic hydrocarbons; aromatic hydrocarbons such as toluene, xylene; nitriles such as acetonitrile, propionitrile; ethers such as tetrahydrofuran and the like or mixtures thereof.
The intermediate compound of Formula Va in step (b) may or may not be isolated. The same can be converted in situ, if desired, to the compound of Formula Via in step c).
Step (c) condensation of N-methyl pentylamine of Formula Va.
Suitable solvents which can be used for the reaction include, but are not limited to, C1-C6 straight chain or branched chlorohydrocarbons, hydrocarbons, aromatic hydrocarbons such as toluene, xylene, and the like; nitriles such as acetonitrile, propionitrile and the like; polar solvents like water; or mixtures thereof.
The reaction may optionally be conducted in the absence of any additional solvent, when the reagent methyl acrylate acts the medium for reaction. Suitable
temperatures for conducting the reaction can range from about -15 to 50 0C, or about 10 to 40 0C, or about 25 to 35 0C.
The intermediate compound of Formula Via may or may not be isolated and may be directly hydrolyzed in-situ if desired, to the compound of Formula Vila.
The hydrolysis can be done either in the acidic conditions or basic conditions using suitable acids or bases as required. Suitable acids which can be used for acidic hydrolysis include, but are not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, para-toluene sulfonic acid and the like; organic acids such as oxalic acid, acetic acid, tartaric acid, formic acid and the like.
Suitable bases which can be used for basic hydrolysis include, but are not limited to sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium tertiary butoxide, potassium tertiary butoxide, sodium secondary butoxide, sodium tertiary butoxide and the like; alkali metal hydroxides comprises sodium hydroxide, potassium hydroxide, lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, lithium carbonate and the like; alkali metal hydrides comprises sodium hydride and the like.
The product can be isolated as the acid addition salt or as the base addition salt based on the reagent selected for hydrolysis. Optionally, the salt obtained can be further purified by recrystallization or slurry in a suitable solvent. Recrystallization involves providing a solution of the intermediate in a suitable solvent and then crystallizing the solid from the solution.
Suitable organic solvents which can be used for recrystallization or slurry include but are not limited to alcoholic solvents such as methanol, ethanol, isopropyl alcohol, n- propanol, and the like; halogenated solvents such as dichloromethane, 1 ,2- dichloroethane, chloroform, carbon tetrachloride and the like; esters such as ethyl
acetate, n-propyl acetate, n-butyl acetate, t-butyl acetate and the like; ether solvents such as diethyl ether.dimethyl ether, di-isopropyl ether, methyl tertiary-butyl ether, tetrahydrofuran, 1 ,4-dioxane and the like; nitrile solvents such as acetonitrile, propionitrile and the like; and mixtures thereof in various proportions.
The concentration of the intermediate in the solvent can range from 40 to 80% or more. For recrystallization, a solution can be prepared at an elevated temperature if desired to achieve a desired concentration. Any temperature is acceptable for the dissolution as long as a clear solution is obtained and is not detrimental to the drug substance chemically or physically. The solution may be brought down to room temperature for further processing if required or an elevated temperature may be used.
The compound obtained can be further dried suitably using a tray dryer, vacuum oven, air oven, fluidized bed drier, spin flash dryer, flash dryer and the like. The drying can be carried out at temperatures of about 35 0C to about 70 0C. The drying can be carried out for any desired time periods to achieve the desired product purity, times from about 1 to 20 hours, or longer, frequently being sufficient.
In an embodiment, the hydrolysis is carried out using hydrochloric acid and the acid addition salt formed is the hydrochloride salt of Formula Villa.
Formula Villa
The salt of Formula Villa obtained according to the process of the present invention is highly pure. It has a purity of not less than 95% and contains less than 1 % of the individual process related impurities.
Step d) reaction of 3-(N-methyl-N-pentylamino) propanoic acid or its salt of Formula Vila.
Suitable phosphonating agents which can be used for the reaction include, but are not limited to, phosphorous acid in combination with any one of phosphorous trichloride, phosphorous pentachloride, phosphorous oxy trichloride, phosphorous tribromide, phosphorous pentabromide, phosphorous oxybromide and the like.
Diluent is an inert substance used to dilute the reaction medium. Suitable diluents which can be used include, but are not limited to, hydrocarbons such as Ci to Cβ straight chain, branched, or cyclic hydrocarbons; aromatic hydrocarbons such as N- pentane, n-hexane, n-heptane, cyclohexane, toluene, 4-chloro toluene, xylene, and the like; nitriles such as acetonitrile, propionitrile, and the like.
Suitably other diluents like chlorinated hydrocarbon solvents such as Ci to Ce straight chain or branched chain chlorohydrocarbons including dichloromethane, ethylene dichloride, chloroform, and carbon tetrachloride; chlorinated aromatics such as chlorobenzene, dichlorobenzene, and the like; ethers such as tetrahydrofuran; alkyl sulfonic acids such as methanesulfonic acid, toluene sulfonic acid, paraffin oil, pyridine, 2-methyl pyrrolidone, and the like can be used in combination with diluents such as methanesulfonic acid, triphenyl phosphine, pyridine, paraffin oil, morpholine and the like.
In an embodiment, the above mentioned diluents can also be used for preparation of other bis-phosphonic acid compounds like alendronic acid, risedronic acid, zoledronic acid, ibandronic acid, minodronic acid, neridronic acid, and olpadronic acid and the like.
Suitable temperatures for conducting the reaction range from about 20 to about 200 0C, or from about 20 to about 100 °C.
In an embodiment, the diluent used for the preparation of ibandronic acid and its salts is a combination of chlorobenzene and methane sulfonic acid, and the phosphonating agent is a combination of phosphorus acid and phosphorous trichloride.
The reaction comprises taking a mixture of chlorobenzene and 3-(N-methyl-N- pentylamino) propanoic acid or its salt of Formula Vila, and adding phosphorous acid to it. Then phosphorous trichloride and methanesulfonic acid are added alternately in lots.
The alternate addition in lots of phosphorus trichloride and methanesulfonic acid helps in eliminating their reacting with each other to form methanesulfonyl chloride, and hence the phosphorus trichloride added reacts with 3-(N-methyl-N-pentylamino) propanoic acid for the required product.
The mole ratio of methanesulfonic acid to the starting material 3-(N-methyl-N- pentylamino) propanoic acid or its salt of Formula Vila may range from about 0.8 to 1 moles per mole of the starting material. It is important to maintain the mole ratio within the said limits as a mole ratio less than or more than the given range effects the yield of the product since the excess of methanesulfonic acid if present in the reaction medium reacts with the phosphorus trichloride making it unavailable for the desired reaction.
The product ibandronic acid which is formed in insoluble in chlorobenzene and hence separates as a gum when it is formed in the reaction medium, suitably methanesulfonic acid is added slowly to the reaction medium such that the exothermicity caused during the addition can be controlled and the product formed is dissolved.
The ibandronic acid formed in the reaction mixture is then directly converted to its base addition salts by adding the required moles of base to the reaction medium containing ibandronic acid.
The reaction medium containing the ibandronic acid is highly acidic, hence pH is suitably adjusted to 1.0 to 1.8 using a suitable base to form the required salt. Ibandronic acid is capable of forming either mono or dibasic salts. Hence depending on the pH to which the reaction medium is adjusted, mono basic or dibasic salts are formed. The pH of the reaction medium is important since it determines the nature of the salt. When a mono basic salt is proposed to be formed, the pH of the reaction medium containing ibandronic acid is adjusted to about 1.0 to about 1.8; and when a dibasic salt is proposed to be formed the pH of the reaction medium is adjusted to about 3.0 to about 5.0.
Suitable bases which can be used for salt formation include, but are not limited to alkali metal alkoxides such as potassium alkoxide, sodium methoxide; alkali metal hydroxides such as sodium hydroxide, potassium hydroxide; alkali metal carbonates such as sodium carbonate, sodium bicarbonate; amines such as tertiarybutylamine, dicyclohexylamine and the like. In an embodiment, the base used is sodium hydroxide and the salt formed is ibandronate sodium.
lbandronate sodium thus formed may optionally be further purified by recrystallization or slurry in a suitable solvent. Recrystallization involves providing a solution of ibandronate sodium in a suitable solvent and then crystallizing the solid from the solution.
Suitable organic solvents which can be used for recrystallization or slurry include but are not limited to alcoholic solvents such as methanol, ethanol, isopropyl alcohol, n- propanol, and the like; ketonic solvents such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; hydrocarbon solvents such as toluene, xylene, n-hexane, n-heptane, cyclohexane and the like; nitrile solvents such as acetonitrile, propionitrile and the like or mixtures thereof in various proportions, or their mixtures with water.
The concentration of ibandronate sodium in the solvent can range from about 0.1 to about 10 g/ml or more. For recrystallization, a solution can be prepared at an
elevated temperature if desired to achieve a desired concentration. Any temperature is acceptable for the dissolution as long as a clear solution of the ibandronate sodium is obtained and is not detrimental to the drug substance chemically or physically. The solution may be brought down to room temperature for further processing if required or an elevated temperature may be used. A higher temperature will allow the precipitation from solutions with higher concentrations of ibandronate sodium resulting in better economies of manufacture.
The compound obtained can be further dried suitably using a tray dryer, vacuum oven, air oven, fluidized bed drier, spin flash dryer, flash dryer and the like. The drying can be carried out at temperatures of about 35 °C to about 70 °C. The drying can be carried out for any desired time periods to achieve the desired product purity, times from about 1 to 20 hours, or longer, frequently being sufficient.
In another embodiment, the present invention provides a process for the preparation of crystalline Form A of ibandronic acid, comprising the steps of: i) reacting N-methyl-N-pentyl amine propionic acid of Formula IV
FORMULA IV with phosphorous acid and phosphorous pentachloride in the presence of a suitable organic solvent ii) isolating using a suitable organic solvent to afford the compound of
Formula I; iii) purifying the compound of Formula I using a suitable organic solvent(s) to afford the pure compound of Formula I; and iv) recovering the desired crystalline Form A of ibandronic acid from step (iii).
Steps (i) and (ii) - reaction of the compound of Formula IV with phosphorous acid and phosphorous trichloride followed by isolating the compound to afford the compound of Formula I.
Suitable organic solvents for isolation include but are not limited to: alcohols such as methanol, ethanol, and isopropanol, butanol and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; esters such as ethyl acetate, n- propyl acetate, n-butyl acetate, tertiary-butyl acetate and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, ethylene dichloride, chloroform and the like; aprotic polar solvents such as N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), N, N- dimethylacetamide (DMA) and the like; or mixtures thereof. In an embodiment of the present invention, the organic solvent is chlorobenzene as solvent.
The reaction temperature for conversion of the compound of Formula IV to the compound of Formula I in step (i) can range from about 0 0C to about 60 0C, or up to the reflux temperature of the solvent used.
Step (iii) purification of the compound of Formula I.
Organic solvents used for purification include but are not limited to any solvent or mixture of solvents in which ibandronic acid is soluble, for example alcohols such as methanol, ethanol, and isopropanol, butanol and the like.
Step (iv) recovering the desired crystalline Form A of ibandronic acid.
Step (iv) can be carried out by using techniques, such as centrifugation, decantation, gravity filtration, vacuum filtration or other techniques known to one skilled in the art for the separation of solids. The wet solid isolated in step (iii) may be dried by using techniques, such as for example fluid bed drying (FBD), aerial drying, oven drying or other techniques known to one skilled in the art.
The drying can be conducted at temperatures of about 0 0C to about 30 0C or about 25 0C to about 30 °C with or without application of a vacuum. Drying can be carried out under inert conditions.
In another embodiment, the present invention provides an improved process for the preparation of substantially pure crystalline Form A of ibandronic acid comprising the step of recrystallisation of crude ibandronic acid using suitable organic solvent(s) for example alcohols such as methanol, ethanol, and isopropanol, butanol and the like or mixtures thereof to afford the desired substantially pure crystalline Form A Ibandronic acid.
As used herein "substantially pure" it is meant that crystalline Form A prepared in accordance with the present invention has a purity of more than about 95% or more than about 99% by HPLC, and contains less than about 0.5%, or less than about 0.1 % by weight of related impurities as characterized by a high performance liquid chromatography ("HPLC").
In an embodiment, the process for the preparation of substantially pure ibandronate sodium monohydrate crystalline Form A, substantially pure ibandronate sodium monohydrate crystalline Form B and a mixture of Form A and Form B comprises: a) providing a solution of ibandronate sodium; b) adding an antisolvent to the solution obtained in step a); c) isolating the separated solid.
Step a) providing a solution of ibandronate sodium.
The solution of ibandronate sodium may be obtained by dissolving the ibandronate sodium in a suitable solvent, or such a solution may be obtained directly from a reaction in which ibandronate sodium is formed.
When the solution is prepared by dissolving ibandronate sodium in a suitable solvent, any form of ibandronate sodium such as the crystalline or amorphous form, including any salts, solvates and hydrates may be utilized for preparing the solution.
Suitable solvents useful in the preparation of the monohydrate of ibandronate sodium include water alone or in combination with an organic solvent, such as for example ketones like acetone, propanone; acetonitrile, and the like; and mixtures thereof. The quantity of solvent used for dissolution is critical in determining the final polymorphic form obtained from the process. When the quantity of solvent is less than 1.6 times to the weight of ibandronate sodium taken, the resulting polymorphic form is ibandronate sodium monohydrate Form A, and when the quantity is more than about 1.6 or more than about 2.0 times, the resulting polymorphic form is ibandronate sodium polymorphic Form B.
Any temperature below 200 °C may be used for dissolution as long as a clear solution is obtained.
The solution can be maintained at this temperature for about 1 minute to any desired time. The solution can optionally be filtered by passing through paper, glass fiber, or other membrane material or a clarifying agent such as celite. Depending upon the equipment used and the concentration and temperature of the solution, the filtration apparatus may need to be preheated to avoid premature crystallization.
The concentration of the solution can be about 0.1 g/ml to about 20 g/ml of the solvent, or it may range form 1 g/ml to 5 g/ml.
Step b) adding an antisolvent to the solution obtained in step a).
A solvent or a mixture of solvents may be added to the solution obtained in step a) to initialize crystallization. Suitable solvents which can be used as anti-solvents include, but are not limited to water, ketonic solvents like acetone, ethyl methyl ketone, and the like or mixtures thereof.
The temperature for addition of the anti-solvent may range from about 40 °C to about 70 °C or from about 50 °C to about 60 °C.
The crystallization may be performed with stirring until the desired crystal yield has been obtained. The crystallization step may further include facilitative measures known to one skilled in the art. For example, crystallization step may further include cooling the solution. The maintenance time during crystallization can range from about 1 to about 20 hours. There is no disadvantage to further extending the crystallization period for getting polymorphic Form A, other than an increased processing expense, and an appropriate time for a given batch size can be determined with little effort by one skilled in the art.
The cooling of the solution may be achieved by simple radiation cooling under atmospheric conditions, accompanied by stirring, or through the use of controlled cooling mechanisms such as for example circulation of cooling media in jacket vessels and the like. Such techniques for rapid and gradual cooling are well known to a person skilled in the art and are all included herein without limitation.
Step c) recovering the separated solid.
Recovery can be performed by any means including, but not limited to, filtration, centrifugation, and decanting. The crystalline form may be recovered from any composition containing the crystalline form and the solvent or solvents including but not limited to a suspension, solution, slurry, and emulsion.
The obtained compound can be further dried under ambient or reduced pressure. For example, drying can be performed under reduced pressure or under atmospheric pressure at a temperature of at about 40 0C to 60 0C, or about 70 0C to 80 0C, or higher. Drying can be performed until a desired residual solvent content has been obtained, such as for a duration of about 2 hours to 24 hours, or about 3 to 6 hours.
Yet another aspect of the present invention provides a mixture of ibandronate sodium monohydrate polymorphs Form A and Form B in any desired ratio of either form to the other and a process for its preparation comprising physically mixing the crystalline forms in any desired ratio.
Physical mixing of the crystalline forms comprises taking the required weights of Form A and Form B to prepare the mixture into a round bottom flask and mixing it by rotating the flask containing it. Other techniques of mixing well known to a person skilled in the art can be used to prepare the mixture.
Thus, according to this aspect Form A of ibandronate sodium monohydrate is mixed with Form B in any ratio from about 0.1 to 99% w/w with respect to the other form. Any form of mixing may be utilized to ensure complete homogeneity of one form in the other. Such forms of mixing could include trituration, blending using different blenders and the like and are within the scope of understanding of a person skilled in the art of processing pharmaceutical powders. The individual crystalline forms or the final mixture may also be subjected to pulverization to reduce the particle size. The particle size and distribution to be used will be determined by the composition into which the mixture is to be incorporated, rates of dissolution and the like and will be within the scope of understanding of a pharmaceutical scientist.
In an embodiment, the mixture is a 45 + 5 to 45 + 5 mixture of Form A to Form B, and the mixing is done by stirring the required weights of Form A and Form B in a flask at an RPM of about 25 to about 30.
In another embodiment, present invention provides an improved process for the synthesis of ibandronate sodium of Formula II,
comprising the steps of reacting 3-(N-methyl-N-pentylamino) propanoic acid hydrochloride of Formula III
FORMULA III
with phosphoric acid, phosphorous trichloride in the presence of suitable diluents and suitable organic solvent to give ibandronic acid of Formula I1
FORMULA I which is subsequently converted into the sodium salt of Formula II.
Suitable diluents that may be used for the reaction includes but are not limited to: methane sulfonic acid, paraffin oil, pyridine, 2-methyl pyrrolidone, and the like; or mixtures thereof, or their combination with water in various proportions. In one embodiment of the present invention the diluent is methane sulfonic acid.
Suitable organic solvents used for isolation include but are not limited to: alcohols such as methanol, ethanol, and isopropanol, butanol and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, tertiary-butyl acetate and the like; nitriles such as acetonitrile, propionitrile and the like; halogenated hydrocarbons such as dichloromethane, ethylene dichloride, chloroform and the like; aprotic polar solvents such as N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), N1N- dimethylacetamide (DMA) and the like; or mixtures thereof, or their combination with water in various proportions.
In another embodiment of the present invention, there is provided an improved process for the preparation of N-methyl pentylamine, having Formula Vl,
'NHCH3
Formula Vl which process comprises the step of reducing N-methylpentanamide, having Formula V
Formula V using suitable reducing agent in the presence of suitable organic solvent to afford N- methyl pentylamine of Formula Vl.
Suitable reducing agents include but are not limited to lithium aluminium hydride, Diisobutylaluminium hydride (DIBAL-H), Sodium Dihydro-bis-(2-Methoxyethoxy) Aluminate (vitride), Sodium borohydride in combination with acetic acid, sodium cyano borohydride and the like. In an embodiment of the present invention the reducing agent is vitride.
Suitable organic solvents include but are not limited to ethers such as diethyl ether, dimethyl ether, diisopropyl ether, methyl tertiary-butyl ether, tetrahydrofuran, 1 ,4- dioxane, and the like; hydrocarbons such as C~ι-C6 straight chain, branched or cyclic hydrocarbons and the like; aromatic hydrocarbons such as toluene, xylene and the like; nitriles such as acetonitrile, propionitrile and the like; or mixtures thereof.
Temperatures for conversion of compound of Formula V to the compound of Formula Vl can range from about 0 0C to about 90 0C.
Still another aspect of the present invention provides crystalline Form A of ibandronic acid, and a process for its preparation.
The crystalline Form A of ibandronic acid has an XRD pattern substantially in accordance with Figure 4, which was measured on a Bruker Axe, D8 Advance Powder X-ray Diffractometer with a Cu K alpha-1 radiation source. The crystalline Form A of ibandronic acid obtained by the above process is characterized by an X-ray powder diffraction pattern using Cu K α-1 radiation with peaks at approximately: 5, 5.9, 7.3, 8.2, 11 , 12.2, 13.9, 14.6, 18.7, 21.2, 22.8, 24.6, 30.7, ± 0.2 degrees 2 theta.
The infrared (IR) spectra of crystalline Form A of ibandronic acid combination of ibandronic acid with pharmaceutically acceptable carriers has been recorded on a Perkin Elmer System Spectrum 1 model spectrophotometer, between 450 cm-1 and 4000 cm-1 , with a resolution of 4 cm-1 in a potassium bromide pellet, the test compound being at the concentration of 1% by mass.
The crystalline form A ibandronic acid is characterized by an infrared absorption spectrum in potassium bromide comprising peaks at about 523.13, 576.98, 672.03, 663.29, 641.13, 933.64, 1054.19, 1152.13, 1381.93, 1473.01 , 1641.95, 2309.79, 2759.58, 2873.35, 2937.52, 2960.91 , and 3089.95 ± 5 cm-1. Crystalline Form A ibandronic acid is also characterized by its infrared absorption spectrum in potassium bromide substantially in accordance with the spectrum of Fig. 14.
The process for its preparation comprises purification of the crude acid obtained according to the process of the present invention or any processes described in the prior art. The purification involves recrystallization in organic solvents. Organic solvents which can be used include but are not limited to any solvent or mixture of solvents in which ibandronic acid is soluble, for example alcohols such as methanol, ethanol, and isopropanol, butanol and the like or mixtures thereof.
lbandronate salts prepared according to the process of the present invention have a D90 less than about 200 μm.
The D-io, D50 and D90 values are useful ways for indicating a particle size distribution. Dgo refers to the value for the particle size for which at least 90 volume percent of the particles have a size smaller than the value. Likewise D50 and Di0 refer to the values for the particle size for which 50 volume percent, and 10 volume percent, of the particles have a size smaller than the value. Methods for determining Di0, D50 and D90 include laser diffraction, such as using Malvern Instruments Ltd. (of Malvern, Worcestershire, United Kingdom) equipment.
Ibandronic acid and its pharmaceutically acceptable salts prepared according to the present invention have a mean particle size of less than about 100 μm, D10 less than 20 μm or less than 50 μm, D50 less than 50 μm or less than 100 μm, and D90 less than 100 μm or less than 200 μm. There is no specific lower limit for any of the D values.
The processes of present invention are simple, cost effective, ecofriendly, reproducible, scalable, robust to produce the desired crystalline Form A of ibandronic acid, which is free flowing and directly compressible into stable formulations.
Still more another aspect of the present invention provides a pharmaceutical composition comprising pure ibandronic acid or its pharmaceutically acceptable salts along with one or more pharmaceutically acceptable carriers, excipients or diluents.
The pharmaceutical composition may be formulated as: solid oral dosage forms such as, but not limited to, powders, granules, pellets, tablets, and capsules; liquid oral dosage forms such as but not limited to syrups, suspensions, dispersions, and emulsions; and injectable preparations such as, but not limited to, solutions, dispersions, and freeze dried compositions. Formulations may be in the form of immediate release, delayed release or modified release. Further, immediate release compositions may be conventional, dispersible, chewable, mouth dissolving, or flash melt preparations, and modified release compositions that may comprise hydrophilic or hydrophobic, or combinations of hydrophilic and hydrophobic, release rate controlling substances to form matrix or reservoir or combination of matrix and reservoir systems. The compositions may be prepared by direct blending, dry granulation or wet granulation or by extrusion and spheronization. Compositions may be presented as uncoated, film coated, sugar coated, powder coated, enteric coated or modified release coated. Compositions of the present invention may further comprise one or more pharmaceutically acceptable excipients.
Pharmaceutically acceptable excipients that find use in the present invention include, but are not limited to: diluents such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sugar and the like; binders such as acacia, guar gum, tragacanth, gelatin, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, pregelatinized starch and the like; disintegrants such as starch, sodium starch glycolate, pregelatinized starch, crospovidone, croscarmellose sodium, colloidal silicon dioxide and the like; lubricants such as stearic acid, magnesium stearate, zinc stearate and the like; glidants such as colloidal silicon dioxide and the like; solubility or wetting enhancers such as anionic or cationic or neutral surfactants; complex forming agents such as various grades of cyclodextrins, resins; release rate controlling agents
such as hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, methyl cellulose, various grades of methyl methacrylates, waxes and the like. Other pharmaceutically acceptable excipients that are of use include but are not limited to film formers, plasticizers, colorants, flavoring agents, sweeteners, viscosity enhancers, preservatives, antioxidants and the like.
In the compositions of present invention ibandronic acid or its pharmaceutically acceptable salts is a useful active ingredient in the range of 0.5 mg to 500 mg, or 1 mg to 250 mg, per dosage form unit.
Certain specific aspects and embodiments of the present invention will be explained in more detail with reference to the following examples, which are provided by way of illustration only and should not be construed as limiting the scope of the invention in any manner.
EXAMPLE 1 : PREPARATION OF IBANDRONIC ACID CRYSTALLINE FORM A
N-methyl-N-pentyl propionic acid of Formula IV (50 g) was charged into a 4-neck round bottom flask containing chlorobenzene (350 ml), and phosphorous acid and heated to about 80 0C to about 85 0C. Phosphorous trichloride (52 ml) was added slowly over a period of about 20-30 minutes and the reaction mass was stirred for about 4 to about 5 hours to a temperature of about 85 0C to about 90 0C. The reaction mass was cooled to about 60 0C -65 0C followed and water (250 ml) was slowly added over a period of about 30 to about 45 minutes. The separated solid was filtered through celite and the organic and aqueous layers were separated.
The filtrate was charged into a clean and dry round bottom flask followed by heating to about 95 0C to about 100 0C for about 16 to about 17 hours. The resultant filtrate was distilled completely under vacuum. The obtained residue was cooled to about 25 0C to about 30 0C followed by addition of isopropyl alcohol (100 ml) and the resultant suspension was stirred over a period of about 10 to about 12 hours. The separated solid was filtered and the solid was washed with isopropyl alcohol (10 ml).
The solid obtained was dried at about 50 0C to about 55 °C under vacuum over a period of about 8 to aboutiO hours to afford 10.3 g of a crude form of title compound.
To the above-obtained crude compound methanol (70 ml) was charged followed by stirring for about 1 to about 2 hours. The solid was filtered and dried at about 25 0C to about 35 0C under vacuum for about 6 to about 7 hours to afford 2.4 g of crystalline Form A of ibandronic acid, with a purity by HPLC 95.36% and having the X-ray powder diffraction pattern of Fig. 13 with peaks approximately at: 5, 5.9, 7.3, 8.2, 10.9, 12.2, 13.9, 4.6, 18.7, 21.2, 22.8, 24.6, 30.7, ± 0.2 degrees 2 theta.
The crystalline form A of ibandronic acid is characterized by an infrared absorption spectrum in potassium bromide comprising peaks at about 523.13, 576.98, 672.03, 663.29, 641.13, 933.64, 1054.19, 1152.13, 1381.93, 1473.01 , 1641.95, 2309.79, 2759.58, 2873.35, 2937.52, 2960.91 , and 3089.95 ± 5 cm-1. Crystalline Form A ibandronic acid is also characterized by its infrared absorption spectrum in potassium bromide substantially in accordance with the spectrum of Fig. 14.
EXAMPLE -2: PROCESS FOR THE PREPARATION OF IBANDRONATE SODIUM (FORMULA II)
3-(N-methyl-N-pentylamino) propanoic acid hydrochloride of Formula III (20 mg) was charged into a round bottom flask containing chlorobenzene (140 ml) and phosphorous acid (15.6 g). The contents were heated to about 75 0C to about 80 0C and phosphorous trichloride (20.8 ml) was added slowly for about 20 to about 30 minutes, followed by addition of methane sulfonic acid (10 ml) for a period of about 20 to about 30 minutes. The reaction mass was stirred for about 3 to about 4 hours at a temperature of about 90 0C to about 100 0C followed by cooling to about 50 0C to about 60 0C. Water (100 ml) was added slowly over a period of about 15 to about 20 minutes followed and the reaction mass was filtered through celite. The organic layer and aqueous layer were separated. The separated aqueous layer was charged in to the fresh round bottom flask and heated to about 95 0C to about 100 0C for about 16 to about 18 hours followed by cooling to about 0 0C to about 10 0C. Sodium hydroxide
(9.4 g) was added slowly followed by addition of methanol (280 ml) and stirred for about 4 to about 5 hours. The separated solid was filtered and the solid was kept for sucking for about 15 to about 30 minutes.
The above-obtained wet solid (28 g) was charged into a round bottom flask containing water (56 ml) and heated to about 60 0C to about 70 0C and maintained for about 30 to about 45 minutes followed by cooling the reaction mass to about 25 0C to about 30 0C. Methanol (112 ml) was added in to the reaction mass and stirred for about 30 to about 45 minutes. The separated solid was filtered and the solid was washed with methanol (20 ml) and kept for sucking for about 30 to about 45 minutes. The filtered solid was charged into a round bottom flask containing water (50 ml) and the contents were heated to about 65 0C to about 70 0C for about 45 to about 60 minutes. Acetone (200 ml) was added into the reaction mass and stirred for about 20 to about 30 minutes. The separated solid was filtered and the solid was washed with acetone (50 ml) and kept for sucking for about 30 to about 45 minutes. The solid obtained was dried to about 45 0C to about 50 0C for about 3 to about 4 hours to afford 16 gm of title compound as a solid with purity by HPLC 99.76%.
EXAMPLE 3: PREPARATION OF N-METHYLPENTYLAMINE (FORMULA VI)
N-methylpentanamide of Formula V (40 g) was charged into a round bottom flask containing toluene (200 ml) followed by stirring for about 5 to about 10 minutes. The aqueous layer and toluene layer were separated and kept aside. Sodium Dihydro-bis- (2-Methoxyethoxy) Aluminate (vitride) (210 ml) and toluene (200 ml) were charged into a clean and dry round bottom flask followed by stirring for about 5 to about 10 minutes. The above-obtained N-methylpentanamide dissolved in toluene was added drop wise slowly over about 45 to about 60 minutes at a temperature of about 25 °C to about 30 0C. The resultant reaction mass was stirred for about 7 to about 8 hours at about 25 0C to about 30 0C followed by cooling to about 5 0C to about 10 0C. Sodium potassium tartarate (120 g) was dissolved in water (800 ml) and added drop wise slowly over a period of about 30 to about 45 minutes at about 0 0C to about 10 0C followed by stirring for about 10 to about 15 minutes. The organic and aqueous layers were separated and
the aqueous layer was extracted with toluene (120 ml) followed by separation of the organic and the aqueous layers. Both the organic layers were combined and the total organic layer was washed with water (2x80 ml) followed by separation of the organic and the aqueous layers.
Purity by Gas chromatography of the title compound is 76.792%.
EXAMPLE 4 - PREPARATION OF METHYL PENTANOATE (FORMULA Ilia):
100 g of valeric acid and 400 ml of methanol were taken into a round bottom flask and stirring given. 104 ml of sulfuric acid was added to the mixture slowly at about 30 °C. The reaction mass was maintained at about 26 °C for about 1 hour. 300 ml of water was added to the reaction mass and stirred for about 10 minutes. 200 ml of dichloromethane was added to it and stirred for another about 15 minutes. The organic layer was separated and the aqueous layer was extracted into 300 ml of dichloromethane. The combined organic layer was distilled atmospherically at about 55 °C to get the product in the form of a residue. Purity by GC: 97.34%.
EXAMPLE 5 - PREPARATION OF N-METHYL PENTANAMIDE (FORMULA IVa)
100 g of crude methyl pentanoate obtained by a process similar to one described in Example 4, and 400 ml of methylamine were taken into a round bottom flask and stirring given at 27 0C. The reaction mass was maintained at about 27 °C for about 5 hours. 300 ml of water was added to the reaction mass and stirred for 15 minutes. 200 ml of dichloromethane was added to it and stirred for 5 minutes. The organic layer was separated and aqueous layer was extracted into 300 ml of dichloromethane. The combined organic layer was distilled atmospherically at a temperature of 49 0C to get a residue.
Purity by GC: 97.8%.
EXAMPLE 6 - PREPARATION OF N-METHYL PENTYLAMINE (FORMULA Va):
50 g of N-methyl pentanamide obtained as per the process given in Example 5 and 250 ml of toluene was taken into a round bottom flask and stirring given at about 28
0C. The organic layer was dried over sodium sulfate. A solution of 262.5 ml of vitride in 250 ml of toluene was taken into a separate round bottom flask and stirred for about 5 minutes. The solution of N-methyl pentanamide in toluene prepared above was added to the mixture of vitride in toluene at about 28 °C. The reaction mass was maintained at about 28 0C for about 5 hours and then cooled to about 4 0C. A solution of 150 g of sodium potassium tartarate in 1000 ml of water was added to the above reaction mass slowly. The reaction mass temperature was raised to about 27 °C. The organic layer was separated and the aqueous layer was extracted into 50 ml of toluene. The combined organic layer was washed with 200 ml of water in two equal lots. Purity by GC: 90.67%.
EXAMPLE 7 - PREPARATION OF N-METHYL PENTYLAMINE (FORMULA Va)
250 ml of 1 ,4-dioxane was added to 70 g of n-methyl pentanamide prepared by a process similar to one described in Example 5 and cooled to about 10 °C. 20 g of sodium borohydride was added to the reaction mass under stirring. Then a mixture of 35 ml of acetic acid and 70 ml of 1 ,4-dioxane was added to the reaction mass at about 10 °C. The contents were heated to about 90 0C and maintained for about 3 hours. Reaction completion was confirmed by thin layer chromatography and the reaction mass was cooled to about 10 °C. 500 ml water of was added to the reaction mass slowly and then pH was adjusted to 0.4 with 75 ml of 36% aqueous hydrochloric acid at about 10 °C. The aqueous reaction mass was washed with 400 ml of dichloromethane in four equal lots to remove impurities. The pH was then adjusted to 12.2 with 50% aqueous sodium hydroxide solution. The reaction mass was extracted with 1000 ml of dichloromethane in five equal lots and the organic layer was progressed to the next step.
EXAMPLE 8 - PREPARATION OF 3-(N-METHYL-N-PENTYLAMINO) PROPANOATE (FORMULA VIa)
The organic layer obtained by a process similar to one described in Example 6 was taken (containing 21 g of N-methylpentylamine). 69 ml of methyl acrylate was added to it and maintained at about 28 °C for about 15 hours. Reaction completion was
checked using thin layer chromatography. After the reaction was completed, the organic layer was proceeded to the next stage. Purity by GC: 92.45%.
EXAMPLE 9 - PREPARATION OF 3-(N-METHYL-N-PENTYLAMINO) PROPANOIC ACID HYDROCHLORIDE (FORMULA VIIa):
40 g of 3-(N-methyl-N-pentylamino) propanoate prepared as per the process given in Example 8 and 90ml of 4 normal hydrochloric acid solution were taken into a round bottom flask and stirred for about 10 minutes. The aqueous layer was separated and the organic layer was extracted into 23 ml of acidic water. The combined aqueous layer was taken into another round bottom flask and heated to about 80 0C. The reaction mass was maintained at about 80 °C for about 11 hours. The reaction mass was then taken into a Bucchi Rotavapor flask and distilled off under a vacuum of 33 mm/Hg at about 82 °C. The remaining residue was cooled to about 30 0C and 150 ml of ethyl acetate was added. The mixture was further cooled to about 5 °C and maintained for about one hour. The separated solid was filtered and washed with 20 ml of ethyl acetate. The wet material was dried at about 34 0C for about 4 hours to yield 15 g of the title compound.
EXAMPLE 10 - PREPARATION OF 3-(N-METHYL-N-PENTYLAMINO) PROPANOIC ACID HYDROCHLORIDE (FORMULA VIIIa):
50 g of crude 3-(N-methyl-N-pentylamino) propanoic acid hydrochloride and 150 ml of acetone was taken into a round bottom flask and heated to about 50 0C. The reaction mixture was maintained at about 50 °C for one hour. The mixture was then cooled to about 30 0C and 300 ml of ethyl acetate was added to it. The mixture was stirred at about 30 °C for about 40 minutes. The separated solid was filtered and washed with 20 ml of ethyl acetate. The wet solid was dried at about 54 °C for about 6 hours to yield 47.5 g of the title compound.
Purity by GC: 99.8%.
EXAMPLE 11 - PREPARATION OF IBANDRONATE SODIUM BY USING CYCLOHEXANE AS DILUENT:
10 g of 3-(N-methyl-N-pentylamino) propanoic acid hydrochloride was charged into a round bottom flask containing 70 ml of cyclohexane. 8.5 g of phosphorous acid was charged to the reaction mass and then heated to about 5 0C. 12.5 ml of phosphorous trichloride was added slowly. The reaction mass was stirred for about 6 hours and then cooled to about 28 °C. 70 ml of water was added slowly and the contents were heated to about 75 0C. The reaction mass was stirred for about 35 minutes and then filtered through a flux calcined diatomaceous earth (Hyflow) bed. The aqueous layer was then separated from the filtrate and heated to 95 °C in another flask. The aqueous layer was stirred at same temperature for about 23 hours and then cooled to about 8 0C. 140 ml of methanol was added and the contents were stirred for about 20 minutes. 2.5 g of sodium hydroxide was charged and the mixture was stirred for about 7 hours at about 4 0C. Another 2.5 g of sodium hydroxide were charged and stirred for about 5 hours at about 5 0C. The separated solid was filtered and washed with 20 ml of methanol. The solid was dried at about 55 °C for about 8 hours to afford 8.5 g of the title compound as crystalline solid.
EXAMPLE 12- PREPARATION OF IBANDRONATE SODIUM BY USING ANISOLE AS DILUENT:
10 g of 3-(N-methyl-N-pentylamino) propanoic acid hydrochloride was charged into a round bottom flask containing 70 ml of anisole. 8.5 g of phosphorous acid was charged to the reaction mass and then heated to about 84 °C. 12.5 ml of phosphorous trichloride was added slowly at about 85 0C. The reaction mass was heated to about 95 0C and maintained for about 3 hours. It was then cooled to about 61 0C and 70 ml of water was added at about 61 °C. The contents were heated again to about 78 °C and stirred for about 15 minutes. The reaction mass was cooled to about 27 0C and filtered through a flux calcined diatomaceous earth (Hyflow) bed. The aqueous layer was separated from the filtrate and heated to about 95 0C in another flask. The aqueous layer was stirred at about 95 °C for about 19 hours and then cooled to about 5 0C. 140
ml of methanol was then added and the contents were stirred for about 20 minutes. 2.5 g of sodium hydroxide was charged and stirred for about 5 hours and 25 minutes at about 3 0C. Another 1.0 g of sodium hydroxide was added and stirred for about 4 hours and 20 minutes at about 3 0C. The separated solid was filtered and washed with 20 ml of methanol. The solid was dried at about 55 0C for about 6 hours to afford 7.0 g of the title compound as crystalline solid.
EXAMPLE 13 - PREPARATION OF IBANDRONATE SODIUM BY USING 4- CHLOROTOLUENE AS DILUENT:
7.0 g of 3-(N-methyl-N-pentylamino) propanoic acid hydrochloride was charged into a round bottom flask containing 50 ml of 4-chlorotoluene and then heated to about 80 °C. 10 ml of phosphorous trichloride was added slowly at about 84 °C and stirred for about 1 hour 35 minutes. It was then cooled to about 45 °C and 9.8 g of phosphorous acid was charged to the reaction mass. The reaction mass was heated to about 95 0C and stirred for about 2 hours 30 minutes at about 97 0C. The reaction mass was cooled to about 64 °C and 50 ml of water was added slowly at about 64 °C. The contents were heated again to about 75 °C and stirred for about 15 minutes. The reaction mass was filtered through a flux calcined diatomaceous earth (Hyflow) bed and aqueous layer separated from the filtrate was heated to about 95 °C in another flask. The aqueous layer was stirred at about 95 °C for about 19 hours and then cooled to about 5 0C. 100 ml of ethanol was added and the contents were stirred for about 20 minutes. 5.8 g of sodium hydroxide was added and stirred for about 8 hours at about 4 °C. The solid was separated, filtered and washed with 50 ml of ethanol. The solid was dried at about 54 0C for about 6 hours 30 minutes to afford 4.8 g of the title compound as crystalline solid.
EXAMPLE 14 - PREPARATION OF IBANDRONATE SODIUM MONOHYDRATE FORM B USING MIXTURE OF CHLOROBENZENE AND METHANE SULFONIC ACID AS DILUENT:
50 g of 3-(N-methyl-N-pentylamino) propanoic acid hydrochloride, 350 ml of chlorobenzene, and 39 g of phosphorous acid were taken into a round bottom and
stirring given. The reaction mass was heated to about 80 °C, and 41.6 ml of phosphorous trichloride was added to it at about 80 to 83 °C. Immediately after the addition of phosphorous trichloride, 10 ml of methanesulfonic acid was added to the reaction mass slowly. After addition of the methanesulfonic acid was completed, another 10.4 ml of phosphorous trichloride was added to the reaction mass. Another 40 ml of methanesulfonic acid was added to the reaction mass slowly. The reaction mass was then heated to about 96 0C and maintained for about 3 hours. The reaction mass was then cooled to about 63 °C and 250 ml of water was added to it slowly. The reaction mass was then filtered and the layers separated. The aqueous layer was taken into another round bottom flask and stirred. The aqueous layer was heated to about 99 0C and maintained for about 14 hours. The aqueous layer was then cooled to about 5 0C and pH of the aqueous layer was adjusted to 1.8 using 48% aqueous sodium hydroxide solution. 700 ml of methanol was added to the aqueous layer and maintained at about 5 0C for about 4 hours 25 minutes. The separated solid was filtered and washed with 10 ml of methanol. The wet solid was taken into another round bottom flask and 220 ml of water was added to it. The mixture was heated to about 80 °C and checked for clear dissolution. Once clear dissolution was obtained, the mixture was cooled to about 30 0C and 560 ml of methanol was added to it. The mixture was maintained at about 30 0C for about 1 hour. The separated solid was filtered and the solid was washed with 50 ml of methanol. The wet compound was again taken into another round bottom flask and 168 ml of water was added to it. The mixture was heated to about 70 °C and about 80 ml of water was distilled off. Then the reaction mass was again heated to about 76 0C and 84 ml of water was added to it. After a clear dissolution was obtained, the reaction mass was cooled to about 30 0C and 500 ml of acetone was added to it. The reaction mass was stirred at about 30 0C for about 1 hour. The separated solid was filtered and washed with 50 ml of acetone. The wet solid was taken into another round bottom flask and 272 ml of water was added t it. The mixture was heated to about 77 0C and checked for clear dissolution. After clear dissolution was obtained, the solution was cooled to about 30 °C and 816 ml of acetone was added to it and stirred for about 10 minutes. The separated solid was filtered and
washed with 50 ml of acetone. The wet solid was dried at about 55 °C for about 16 hours to yield 51.7 g of the title compound. Purity by HPLC: 99.8%.
EXAMPLE 15 - PREPARATION OF SUBSTANTIALLY PURE IBANDRONATE SODIUM MONOHYDRATE CRYSTALLINE FORM A:
50 g of ibandronate sodium was taken and 61.6 ml of water was added to it. The mixture was heated to about 90 °C and checked for clear dissolution. After a clear dissolution was obtained, the solution was filtered under hot condition and the filtrate was cooled to about 50 0C. A mixture of 250 ml of acetone and 50 ml of water was added to the above solution at about 50 0C. The reaction mass was then cooled to about 30 0C and maintained for about 6 hours. The separated solid was filtered and washed with 83.3 ml of acetone. The wet solid was dried at about 60 0C for about 12 hours to yield 47.5 g of the title compound.
EXAMPLE 16 - PREPARATION OF IBANDRONATE SODIUM MONOHYDRATE CRYSTALLINE FORM A:
15 g of ibandronate sodium was taken and 18.5 ml of water was added to it. The mixture was heated to about 90 °C and checked for clear dissolution. After a clear dissolution was obtained, the solution was filtered and the filtrate was cooled to about 60 °C. A mixture of 51.8 ml of acetone and 29 ml of water was taken into another round bottom flask and heated to about 50 0C. The above acetone water mixture was added to the filtrate obtained above. The reaction mixture was cooled to about 30 0C and maintained for about one hour. The separated solid was filtered and the solid was washed with 50 ml of a 1 :1 mixture of acetone and water. The wet solid was dried at about 60 °C for about 21 hours to yield 4.1 g of the title compound.
EXAMPLE 17 - PREPARATION OF 45:65 MIXTURE OF IBANDRONATE SODIUM MONOHYDRATE FORM A AND FORM B:
27.5 g of ibandronate sodium Form A and 25 g of ibandronate sodium Form B were taken into a bucchi rota vapor flask and stirred at an RPM of about 30. The sample was maintained under rotation for about 8 to 10 hours to afford 52.5 g of the desired combination of ibandronate sodium polymorphs Form A to Form B in a weight to weight ratio of about 45% w/w to about 55% w/w.
Claims
1. A crystalline Form A of ibandronic acid.
2. The crystalline Form A of claim 1 , characterized by the X-ray powder diffraction pattern having peak locations substantially in accordance with Fig. 13.
3. The crystalline Form A of claim 1 , characterized by an X-ray powder diffraction pattern using Cu K α-1 radiation with peaks at approximately: 5, 5.9, 7.3, 8.2, 11 , 12.2, 13.9, 14.6, 18.7, 21.2, 22.8, 24.6, 30.7, ± 0.2 degrees 2 theta.
4. The crystalline form A of claim 1 , characterized by an infrared absorption spectrum having peaks locations substantially in accordance with Fig. 14.
5. The crystalline form A of claim 1 , characterized by an infrared absorption spectrum in potassium bromide comprising peaks at about 523.13, 576.98, 672.03, 663.29, 641.13, 933.64, 1054.19, 1152.13, 1381.93, 1473.01 , 1641.95, 2309.79, 2759.58, 2873.35, 2937.52, 2960.91 , and 3089.95 ± 5 cm-1.
6. Crystalline Form A of ibandronate sodium monohydrate containing less than about 2% of crystalline Form B of ibandronate sodium monohydrate.
7. Crystalline Form A of ibandronate sodium monohydrate containing less than about 1 % of crystalline Form B of ibandronate sodium monohydrate.
8. A process for the preparation of crystalline Form A of ibandronic acid, comprising the steps of:
(a) reacting N-methyl-N-pentyl amine propionic acid of Formula IV with phosphorous acid and phosphorous pentachloride in the presence of chlorobenzene and methane sulfonic acid;
(b) isolating using an organic solvent; (c) purifying using an organic solvent; and
(d) recovering the desired crystalline Form A of ibandronic acid.
9. A process for the preparation of substantially pure crystalline Form A of ibandronic, comprising the step of recrystallisation of crude ibandronic acid using an organic solvent.
10. A process for the preparation of ibandronate sodium of Formula II, comprising:
(a) reacting 3-(N-methyl-N-pentylamino) propanoic acid hydrochloride of Formula III with phosphoric acid, phosphorous trichloride, together with a diluent and an organic solvent; and
(b) converting to the sodium salt of Formula II.
11. The process of claim 10, wherein said diluent is mixture of chlorobenzene and methane sulfonic acid.
12. A process for the preparation of N-methyl pentylamine of Formula Vl comprising reducing N-methylpentanamide of Formula V with a reducing agent in the presence of an organic solvent.
13. The process of claim 12, wherein said reducing agent is vitride.
14. A process for preparing ibandronic acid comprising reacting a compound of Formula.
15. The process of claim 14, wherein the reducing agent is selected from a group consisting of sodium bis(2-methoxyethoxy) aluminum hydride, lithium aluminium hydride, sodium borohydride/acetic acid, and diisobutyl aluminium hydride (DIBAL H).
16. The process according to claim 14, wherein the reducing agent used is sodium bis(2-methoxyethoxy) aluminum hydride.
17. The process according to claim 15, wherein the reducing agent used is sodium bis(2-methoxyethoxy) aluminum hydride.
18. The process of claim 14, wherein the compound having Formula IVa is prepared by esterification of the compound of Formula
19. The process of claim 14 further comprises reacting the compound of Formula with methylacrylate to give the compound of Formula
20. A process of claim 18, wherein the esterification is carried out in the presence of an inorganic acid.
21. The process of claim 20, wherein the inorganic acid is sulfuric acid.
22. A process of claim 19, further comprising converting ibandronic acid to its pharmaceutically acceptable salt.
23. The process of claim 9, wherein the alcoholic solvent is methanol.
24. A process for the preparation of ibandronic acid and its salts comprises: a) esterfication of valeric acid of Formula Ma, followed by condensation with methylamine to give N-methylpentanamide of Formula IVa.
Formula Ma Formula IVa b) reduction of N-methylpentanamide of Formula IVa with a suitable reducing agent to afford N-methyl pentylamine of Formula Va;
Formula Va c) condensation of N-methyl pentylamine of Formula Va with methyl acrylate to afford methyl 3-(N-methyl-N-pentylamino)propanoate of Formula Via followed by its hydrolysis to give its salt of Formula Vila;
where X is an inorganic or organic acid, or an inorganic or organic cation. d) reaction of 3-(N-methyl-N-pentylamino) propanoic acid or its salt of Formula Vila with phosphonating agent in a suitable diluent to give ibandronic acid of Formula I.
25. The process of claim 24, wherein said ibandronic acid of Formula I is subsequently be converted into its salt of Formula IXa.
Formula IXa where X' is an inorganic or organic cation.
26. The process of claim 24 wherein in step (a) said alcohol is methanol, and the corresponding ester formed is methyl pentanoate of Formula HIa.
Formula HIa
27. The process of claim 24, wherein said hydrolysis is carried out using hydrochloric acid and the acid addition salt formed is the hydrochloride salt of Formula Villa.
Formula Villa
28. A pharmaceutical composition comprising pure ibandronic acid or its pharmaceutically acceptable salts along with one or more pharmaceutically acceptable carriers, excipients or diluents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07813544A EP2046342A4 (en) | 2006-07-28 | 2007-07-30 | Crystalline form a of ibandronic acid and process for the preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82063806P | 2006-07-28 | 2006-07-28 | |
US60/820,638 | 2006-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008014510A2 true WO2008014510A2 (en) | 2008-01-31 |
WO2008014510A3 WO2008014510A3 (en) | 2008-11-20 |
Family
ID=38982427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/074738 WO2008014510A2 (en) | 2006-07-28 | 2007-07-30 | Crystalline form a of ibandronic acid and process for the preparation |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2046342A4 (en) |
WO (1) | WO2008014510A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008131160A1 (en) * | 2007-04-19 | 2008-10-30 | Dr. Reddy's Laboratories Ltd. | Ibandronate sodium polymorphs |
WO2009042179A1 (en) * | 2007-09-24 | 2009-04-02 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ibandronic acid and processeses for the preparation thereof |
WO2012007021A1 (en) * | 2010-07-14 | 2012-01-19 | Pharmathen S.A. | Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof |
WO2013109198A1 (en) * | 2012-01-18 | 2013-07-25 | Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ | Processes for the preparation of sodium ibandronate monohydrate polymorphs a, b and mixture of polymorphs a with b |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1716161B1 (en) * | 2003-12-23 | 2011-05-04 | Alchymars S.p.A. | Ibandronic acid monosodium salt in the amorphous form |
MX2007000087A (en) * | 2004-06-23 | 2007-11-06 | Teva Pharma | Solid and crystalline ibandronic acid. |
PT1713489E (en) * | 2004-08-23 | 2011-03-03 | Teva Pharma | Crystalline form of ibandronate sodium and processes for preparation thereof |
US7214818B2 (en) * | 2004-10-29 | 2007-05-08 | Hoffmann-La Roche Inc. | Method for synthesizing bisphosphonate |
WO2007074475A2 (en) * | 2005-12-27 | 2007-07-05 | Natco Pharma Limited | Novel polymorphic forms of ibandronate |
-
2007
- 2007-07-30 EP EP07813544A patent/EP2046342A4/en not_active Withdrawn
- 2007-07-30 WO PCT/US2007/074738 patent/WO2008014510A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of EP2046342A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008131160A1 (en) * | 2007-04-19 | 2008-10-30 | Dr. Reddy's Laboratories Ltd. | Ibandronate sodium polymorphs |
WO2009042179A1 (en) * | 2007-09-24 | 2009-04-02 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ibandronic acid and processeses for the preparation thereof |
WO2012007021A1 (en) * | 2010-07-14 | 2012-01-19 | Pharmathen S.A. | Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof |
WO2013109198A1 (en) * | 2012-01-18 | 2013-07-25 | Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ | Processes for the preparation of sodium ibandronate monohydrate polymorphs a, b and mixture of polymorphs a with b |
Also Published As
Publication number | Publication date |
---|---|
WO2008014510A3 (en) | 2008-11-20 |
EP2046342A4 (en) | 2011-05-04 |
EP2046342A2 (en) | 2009-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7511174B2 (en) | Solid and crystalline ibandronic acid | |
JP4559431B2 (en) | Solid and crystalline ibandronate sodium and process for its preparation | |
JP6039755B2 (en) | Ibandronate polymorph B | |
JP4560548B2 (en) | Ibandronate manufacturing method | |
US20080255366A1 (en) | Crystalline Trihydrate of Zoledronic Acid | |
WO2008014510A2 (en) | Crystalline form a of ibandronic acid and process for the preparation | |
WO2007074475A2 (en) | Novel polymorphic forms of ibandronate | |
CZ20033019A3 (en) | Polymorphs of fexofenadine hydrochloride | |
US7858634B2 (en) | Amorphous 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid monosodium salt and process for the preparation thereof | |
WO2014091386A2 (en) | An improved process for preparation of minodronic acid | |
AU2003206755A1 (en) | Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds | |
US20100125149A1 (en) | Ibandronate sodium polymorphs | |
US20080009466A1 (en) | Crystalline forms of ibandronic acid and processes for preparation thereof | |
JP5220843B2 (en) | Multi-step synthesis of ibandronate | |
WO2006129056A2 (en) | Process and novel salt | |
US10815257B2 (en) | Polymorph of sodium neridronate and preparation process thereof | |
US20090012182A1 (en) | Crystal forms of O-desmethylvenlafaxine succinate | |
US20090149427A1 (en) | Pharmaceutically acceptable salts and hydrates of risedronic acid | |
US11512104B2 (en) | Process for the preparation of the polymorph F of sodium neridronate | |
US10611793B1 (en) | Solid state forms of obeticholic acid salts | |
WO2009003001A2 (en) | Preparation of risedronate sodium hemi-pentahydrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07813544 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 466/CHENP/2009 Country of ref document: IN |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007813544 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |